CSIMarket Company Name, Ticker, Customers, else..
 

Oncternal Therapeutics Inc   (NASDAQ: ONCT)

Oncternal Therapeutics Inc 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

ONCT Sales vs. its Competitors Q3 2024


Comparing the current results to its competitors, Oncternal Therapeutics Inc reported Revenue increase in the 3 quarter 2024 by 175.98 % year on year.
The sales growth was above Oncternal Therapeutics Inc 's competitors' average revenue growth of 11.29 %, achieved in the same quarter.

• List of ONCT Competitors





Revenue Growth Comparisons




Net Income Comparison

Oncternal Therapeutics Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 0.09 %

<<  ONCT Stock Performance Comparisons





  

Overall company Market Share Q3 2024
Due to outstanding performance in Overall company, revenue grew by 175.98 % Oncternal Therapeutics Inc improved its market share, to approximately 0 %.




<<  More on ONCT Market Share.
 
*Market share is calculated based on total revenue.

  News about Oncternal Therapeutics Inc Contracts

Advancing Precision Medicine: Oncternal Therapeutics Completes Enrollment and Dosing In...

May 30, 2024
 Oncternal Advances Phase 1/2 Study of ONCT-534 for Treatment of Metastatic Castration-Resistant Prostate CancerOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies, has recently completed enrollment and begun dosing for the fifth dose cohort in its Phase 1/2 study of ONCT-534. This study aims to evaluate the efficacy and safety of ONCT-534 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor pathway inhibitors (ARPI).Metastatic castration-resistant prostate cancer is a challenging and life-threatening condition that occurs...

Oncternal Therapeutics Strengthens Research Team with Inducement Award to New Hire

February 1, 2024
 In a recent press release, Oncternal Therapeutics, a prominent clinical-stage biopharmaceutical company specializing in the development of innovative oncology therapies, announced the approval of an inducement award for Damien Bresson. Bresson is joining Oncternal as the Senior Director of Preclinical and Translation Science. This article will outline the significance of this induction and assess its potential impact on the company s research and development endeavors.The appointment of Damien Bresson as the Senior Director of Preclinical and Translation Science demonstrates Oncternal Therapeutics commitment to strengthening its research team and advancing its position in the highly competitive field of onc...





Publicly Traded Peers of Oncternal Therapeutics Inc




Decoy Therapeutics Inc
Share Performance



-29.03%
30 Days
Decoy Therapeutics Inc
Profile

Decoy Therapeutics Inc. develops peptide conjugate therapeutics utilizing artificial intelligence and machine learning technologies.

More about Decoy Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1.638 mill. $ - mill. $ -13.034 mill.


Adagene Inc
Share Performance



-3.84%
This Quarter
Adagene Inc
Profile

Adagene Inc is a biotechnology company that develops novel antibody therapeutics for cancer treatment by leveraging its proprietary Dynamic Precision Library platform. Their business model involves partnering with pharmaceutical companies for the development and commercialization of their products.

More about Adagene Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 214.487 mill. $ 7.671 mill. $ -17.609 mill.


Acurx Pharmaceuticals inc
Share Performance



-65.74%
One Year
Acurx Pharmaceuticals inc
Profile

Acurx Pharmaceuticals Inc. operates by developing and commercializing novel antibiotics to address the growing problem of bacterial antibiotic resistance. The company focuses on targeting serious and life-threatening infections caused by multi-drug-resistant bacterial strains. Acurx Pharmaceuticals aims to bring innovative solutions to market through research and development, strategic partnerships, and a strong emphasis on improving patient outcomes.

More about Acurx Pharmaceuticals inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3.860 mill. $ - mill. $ -7.498 mill.


Abivax Sa
Share Performance



-3.64%
Over The Past 5 Days
Abivax Sa
Profile

The company develops, manufactures, and commercializes drug candidates through collaborative partnerships.

More about Abivax Sa's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 7,806.527 mill. $ - mill. $ -376.434 mill.


Abvc Biopharma Inc
Share Performance



-68.41%
One Year
Abvc Biopharma Inc
Profile

ABVC Biopharma Inc is a pharmaceutical company that focuses on the development and commercialization of innovative biopharmaceutical products.

More about Abvc Biopharma Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 21.947 mill. $ - mill. $ -7.050 mill.

175 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Oncternal Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Oncternal Therapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.